Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2/Neu Positive|Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: BIOLOGICAL: HER-2/neu Intracellular Domain Protein|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pertuzumab|OTHER: Placebo|BIOLOGICAL: Polysaccharide-K|BIOLOGICAL: Trastuzumab
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)|National Center for Complementary and Integrative Health (NCCIH)